Showing 73–84 of 192 resultsSorted by latest
Pharma & Biotech
The academic and government segment saw high-single-digit growth in Q4 and low-single-digit growth for the full year, with strong performance in chromatography, mass spectrometry, and research and safety market channels.
EW’s TAVR segment showed progress with the EARLY TAVR trial, which demonstrated better outcomes for asymptomatic severe aortic stenosis patients using the SAPIEN platform compared to standard monitoring.
Novartis (NVS) showed strong financial growth, with 38% revenue increase in constant currencies and 41% excluding Entresto, supporting its goal of 5%+ annual sales growth through 2029.
Roche had positive results for Trontinemab and promising findings in the Prasi trial.
AbbVie expects big growth from Skyrizi and Rinvoq, which are projected to generate nearly $24 billion in revenue by 2025, up by $6 billion
In 2024, revenue grew 32% from 2023, exceeding initial guidance by $4 billion, with a 45% increase in the Q4FY24 driven by new product momentum.
Johnson & Johnson (JNJ) saw 7% operational sales growth in 2024 (excluding the COVID-19 vaccine) and now has 26 platforms generating over $1 billion annually, including SPRAVATO
Teva Pharmaceutical Industries Ltd. reported financial results for Q4 FY24 and the full year, marking its second consecutive year of growth
DocuSign’s launch of “DocuSign for Developers” at its inaugural DocuSign Discover event marks a strategic expansion of its Intelligent Agreement Management (IAM) platform, positioning the company for operational efficiency, financial growth, and broader market reach.
REGN remains focused on science and innovation, leveraging advanced technology platforms that have led to 13 approved or authorized products worldwide, including five blockbuster drugs and a robust pipeline of approximately 40 product candidates.
Twist Bioscience reported revenue of $88.7 million for Q1FY25, marking a 24% increase compared to $71.5 million in the same period last year.
Dr. Reddy’s growth was driven by its strong presence in the global generics and biosimilars segments.